“We appreciate CB Capital’s detailed evaluation of our proprietary ARTEMIS® T-cell platform and the progress we have made with EB103,” said Dr. Cheng Liu, President and Chief Executive ...
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback